KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

Inhibitors that target the receptor tyrosine kinase (RTK)/Ras/mitogen-activated protein kinase (MAPK) pathway have led to clinical responses in lung and other cancers, but some patients fail to respond and in those that do resistance inevitably occurs (Balak et al., 2006; Kosaka et al., 2006; Rudin...

Full description

Bibliographic Details
Main Authors: Elsa B Krall, Belinda Wang, Diana M Munoz, Nina Ilic, Srivatsan Raghavan, Matthew J Niederst, Kristine Yu, David A Ruddy, Andrew J Aguirre, Jong Wook Kim, Amanda J Redig, Justin F Gainor, Juliet A Williams, John M Asara, John G Doench, Pasi A Janne, Alice T Shaw, Robert E McDonald III, Jeffrey A Engelman, Frank Stegmeier, Michael R Schlabach, William C Hahn
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2017-02-01
Series:eLife
Subjects:
CRISPR-Cas9
drug resistance
lung cancer
Online Access:https://elifesciences.org/articles/18970

Internet

https://elifesciences.org/articles/18970

Similar Items